Summary
Conclusion
the dossier summarised in one paragraphThe computed 12-month bankruptcy probability of DR CELINE DI BLASIO is 2.6% (moderate). The 2025 annual accounts show equity of €157k and a net result of €50k. Equity is growing by ~28.7% per year across the filed fiscal years. The company has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals.
Based on the State Gazette, CBE and 3 annual accounts.
Signals
2 signals · with evidenceSignals are derived from the filed annual accounts and the sector comparison. No composite score: each signal is separately verifiable at the source.
Filing behaviour
From the deposit records, complete market-wide| Year closed | Due by | Filed | Variance | Reference |
|---|---|---|---|---|
| 31-12-2025 | 31-07-2026 | 26-03-2026 | 127 d early | 2026-00062907 |
| 31-12-2024 | 31-07-2025 | 01-07-2025 | 30 d early | 2025-00207243 |
| 31-12-2023 | 31-07-2024 | 24-07-2024 | 7 d early | 2024-00275570 |
Source: the National Bank's deposit records. Those records are complete, including for years whose figures we have not read yet. Filing late covers nearly half the market and is therefore not scored; only not filing, being more than 90 days late and breaking a punctual record carry weight.
Trust signals
2 signalsAdministrative Flags
Bankruptcy probability (12 mo)
Checked model v1 · free for everyoneStatistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Financials
Annual accounts & ratios
Source: NBB · 2025How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Fiscal year | 2025 |
|---|---|
| Deposit | micro |
| Revenue | - |
| EBITDA | €64k |
| Net profit | €50k |
| Cash flow | €51k |
| Staff costs | - |
| Income taxes | €13k |
| Dividends | €31k |
| Total assets | €160k |
| Equity | €157k |
| Debt | €3k |
| of which ≤ 1y | €3k |
| of which > 1y | - |
| Working capital | €157k |
| Employees (FTE) | - |
| 2025 | |
|---|---|
| Current ratio | 53.04 |
| Quick ratio | 53.04 |
| Working capital ratio | 97.8% |
| Solvency | 98.1% |
| Debt / equity | 0.02 |
| Long-term debt ratio | - |
| Interest coverage | 48.17 |
| Gross margin | - |
| Net margin | - |
| ROA | 31.4% |
| ROE | 32.0% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2025 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €160k |
| Fixed assets | 21/28 | €503 |
| Tangible fixed assets | 22/27 | €503 |
| Current assets | 29/58 | €160k |
| Amounts receivable within one year | 40/41 | €23k |
| Cash & bank | 54/58 | €124k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €160k |
| Equity | 10/15 | €157k |
| Contributions / capital | 10/11 | €6k |
| Reserves | 13 | €151k |
| Amounts payable | 17/49 | €3k |
| Amounts payable within one year | 42/48 | €3k |
| Trade debts payable within one year | 44 | €2k |
| Income statement | ||
| Gross operating margin | 9900 | €65k |
| Operating result | 9901 | €64k |
| Financial income | 75 | €1k |
| Financial charges | 65 | €1k |
| Result before taxes | 9903 | €64k |
| Income taxes | 67/77 | €13k |
| Net result for the period | 9904 | €50k |
| Result to be appropriated | 9905 | €50k |
Health barometer
FY 2025 · computedUnlock the full score breakdown, per-year score history and the indicative credit limit from Kantoor S.
See plans →Structure & network
Locations & real estate
Registered office
from the Crossroads BankThis address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Chaussée du Roi Baudouin 135B 327030 MonsEstablishment units
1 locationReal-estate footprint
Source: CBE × cadastre · address linkingParcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 53071A0284/00M003 | Wallonia | 1,986 m² | 1 · 122 m² | 9.2 m · 3 fl. |
| 53061B0086/00Z002 | Wallonia | 1,697 m² | - | - |
Publications
Lifecycle & Insolvency Signals
Belgisch Staatsblad · acts
2 acts19-01-2026 Registered office moved from NOUVELLES to Saint-Symphorien
- RÚE D'ASQUILLIES 13, 7022 NOUVELLES → Chaussée du Roi Baudoin 135, 7030 Saint-Symphorien
30-11-2022 Incorporation of a new SRL
Analysis
Snowflake analysis
financial profile on 5 axesExceptional profile, strong across almost every axis.
All 5 axes are computed from data Checked has read.
Ask AI about this company
Checked AISoon: ask questions about this dossier, risks, curator, sector comparison, answered from the official data on this page.
AI due-diligence brief
Checked AIGenerate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
Credit advice
verdict per customer and amountCompany registry
Company registry (CBE)
Crossroads Bank| Legal nameFR | DR CELINE DI BLASIO |